Efficacy and safety of bevacizumab in recurrent sex cord-stromal ovarian tumors: Results of a phase 2 trial of the Gynecologic Oncology Group Academic Article uri icon

Overview

MeSH Major

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized
  • Neoplasm Recurrence, Local
  • Ovarian Neoplasms
  • Sex Cord-Gonadal Stromal Tumors

abstract

  • Bevacizumab has activity in the treatment of recurrent sex cord-stromal tumors of the ovary, and its toxicity is acceptable. Further investigation is warranted.

publication date

  • February 2014

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4250045

Digital Object Identifier (DOI)

  • 10.1002/cncr.28421

PubMed ID

  • 24166194

Additional Document Info

start page

  • 344

end page

  • 51

volume

  • 120

number

  • 3